Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Abstract
Highly potent, but poorly water-soluble, drug candidates are common outcomes of contemporary drug discovery programmes and present a number of challenges to drug development - most notably, the issue of reduced systemic exposure after oral administration. However, it is increasingly apparent that formulations containing natural and/or synthetic lipids present a viable means for enhancing the oral bioavailability of some poorly water-soluble, highly lipophilic drugs. This Review details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drugs and provides a perspective on the possible future applications of lipid-based delivery systems. Particular emphasis has been placed on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first-pass drug metabolism) and alter enterocyte-based drug transport and disposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“This route becomes quantitatively relevant only for compounds that combine high lipophilicity with appreciable long-chain triglyceride solubility, for which a log P greater than 5 and a lipid solubility above approximately 50 mg/g are commonly cited as approximate thresholds [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“Because lymphatic delivery reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28,29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“For highly lipophilic drugs, a fraction of the absorbed dose can bypass the portal circulation entirely and reach the systemic circulation via the intestinal lymphatics, associated with triglyceride-rich lipoproteins (chylomicrons) assembled within the enterocyte [28,29].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“The extent of transport is highly sensitive to prandial state and to the type and quantity of co-administered lipid, which differ across preclinical study designs and between the fasted conditions typical of first-in-human protocols and the fed conditions under which lymphatic transport is greatest [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“This is especially the case when potent, but highly lipophilic, drug candidates arise from complex chemical scaffolds and multiple high-throughput activity screen”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Items 501–600 of 1,003
Catanzaro, E., Féron, O., Skirtach, A. G., & Krysko, D. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925290 · Cited by 63
A Modified Physiological BCS for Prediction of Intestinal Absorption in Drug Discovery
Zaki, N. M., Artursson, P., & Bergström, C. A. S. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100124f · Cited by 62
Butreddy, A., Narendar, D., & Veerabrahma, K. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1299160 · Cited by 62
Jaisamut, P., Wiwattanawongsa, K., Graidist, P., Sangsen, Y., & Wiwattanapatapee, R. (2017) · AAPS PharmSciTech · doi:10.1208/s12249-017-0857-3 · Cited by 62
Tang, Y., Liu, B., Zhang, Y., Liu, Y., Huang, Y., & Fan, W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115304 · Cited by 61
Benson, H. A., Krishnan, G., Edwards, J., Liew, Y. M., & Wallace, V. P. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.62.06.0005 · Cited by 61
Wu, L., Qiao, Y., Wang, L., Guo, J., Wang, G., He, W., Yin, L., & Zhao, J. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-014-0280-y · Cited by 61
Lu, H. D., Spiegel, A. C., Hurley, A. I., Perez, L. J., Maisel, K., Ensign, L. M., Hanes, J. S., Bassler, B. L., Semmelhack, M. F., & Prud’homme, R. K. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b00151 · Cited by 61
Magnetic Oleosome as a Functional Lipophilic Drug Carrier for Cancer Therapy
Cho, H., Lee, T., Yoon, J., Han, Z., Rabie, H., Lee, K., Su, W., & Choi, J. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19255 · Cited by 61
Solidified nanostructured lipid carrier (S-NLC) for enhancing the oral bioavailability of ezetimibe
Shevalkar, G. B., & Vavia, P. R. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101211 · Cited by 61
Emulsomes: An emerging vesicular drug delivery system
Gill, B., Singh, J., Sharma, V., & Kumar, S. H. (2012) · Asian Journal of Pharmaceutics · doi:10.4103/0973-8398.102930 · Cited by 61
Diwan, R., Ravi, P. R., Pathare, N. S., & Aggarwal, V. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111073 · Cited by 60
Chen, X., Chen, Y., Liu, Y., Zou, L., McClements, D. J., & Liu, W. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13017 · Cited by 60
Nanoparticle oral absorption and its clinical translational potential
Kim, K. S., Na, K., & Bae, Y. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.024 · Cited by 60
Kupikowska-Stobba, B., Niu, H., Klojdová, I., Agregán, R., Lorenzo, J. M., & Kasprzak, M. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.142151 · Cited by 61
Phan, S., Salentinig, S., Gilbert, E. P., Darwish, T. A., Hawley, A. M., Nixon‐Luke, R., Bryant, G., & Boyd, B. J. (2014) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2014.11.026 · Cited by 60
Allam, A. N., Komeil, I. A., Fouda, M. A., & Abdallah, O. Y. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.04.067 · Cited by 60
Fang, G., Tang, B., Liu, Z., Gou, J., Zhang, Y. X., Xu, H., & Tang, X. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.04.016 · Cited by 60
“Secondly, the material should still Over the last few decades, an increasing number of newly developed drugs have been found to be poorly water-soluble and, as a result, these so called ‘brickdust drugs’ often exhibit poor bioavailability (Porter et al., 2007; Rabinow, 2004).”
BackgroundBeloqui, A., Solinís, M. Á., Delgado, A., Évora, C., Isla, A., & Rodríguez‐Gascón, A. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2013.788090 · Cited by 60
“…as promising vehicles for poorly water-soluble compounds (Pouton, 2006; Hauss, 2007; Chen, 2008; Dahan & Hoffman, 2008; Jannin et al., 2008; O’Driscoll & Griffin, 2008; Porter et al., 2007, 2008; Pouton & Porter, 2008; Trevaskis et al., 2008; Chakraborty et al., 2009; Müllertz et al., 2010).”
BackgroundStillhart, C., Imanidis, G., & Kuentz, M. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0999-2 · Cited by 60
Influenza — Time to Target the Host?
Baillie, J. K., & Digard, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmcibr1304414 · Cited by 55
Beg, S., Raza, K., Kumar, R., Chadha, R., Katare, O. P., & Singh, B. (2016) · RSC Advances · doi:10.1039/c5ra24278a · Cited by 60
Deconstructing HPMCAS: Excipient Design to Tailor Polymer–Drug Interactions for Oral Drug Delivery
Ting, J., Navale, T. S., Jones, S. D., Bates, F. S., & Reineke, T. M. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00234 · Cited by 60
Phytosterol nanoparticles with reduced crystallinity generated using nanoporous starch aerogels
Ubeyitogullari, A., & Ciftci, O. N. (2016) · RSC Advances · doi:10.1039/c6ra20675a · Cited by 60
Morgen, M. M., Saxena, A., Chen, X., Miller, W., Nkansah, R., Goodwin, A. K., Cape, J., Haskell, R. J., Su, C., Gudmundsson, O. S., et al. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.04.021 · Cited by 60
“Highly potent compounds may be discovered through these means, but their poor water solubility can lead to numerous challenges during development—particularly, reduced systemic exposure after oral administration [3].”
BackgroundTung, N.-T., Tran, C.-S., Pham, T.-M.-H., Nguyen, H. A., Nguyen, T.-L., Chi, S., Nguyen, D.-D., & Bui, T.-B.-H. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.027 · Cited by 60
“Besides, the components used in SMEDDS like oil, surfactant and cosolvent were well known as solubilizers or permeability enhancers (Pouton, 2000; Porter et al., 2007; Pouton and Porter, 2008; Bala et al., 2016; Yeom et al., 2017) which played the pivotal role in enhancement of drug bioavailability (Rabinow, 2004; Buc…”
Sandhu, P. S., Beg, S., Mehta, F. F., Singh, B., & Trivedi, P. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1060219 · Cited by 59
“Of late, nanostructured drug delivery systems have shown immense promise in enhancing the oral bioavailability of anticancer drugs owing to their ability to circumvent major hiccups responsible for diminution in the oral bioavailability [7,8].”
BackgroundWulff-Pérez, M., de Vicente, J., Martín-Rodríguez, A., & Gálvez-Ruiz, M. J. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.025 · Cited by 59
“…forming a series of colloidal structures, including multiamellar and unilamellar vesicles, mixed micelles and micelles. ydrophobic drugs leave the droplets within these species, which ignificantly increase the solubilization capacity of the small intesine for these drugs (Porter et al., 2007).”
InfluentialJoyce, P. M., Tan, A., Whitby, C. P., & Prestidge, C. A. (2014) · Langmuir · doi:10.1021/la500094b · Cited by 59
Microstructured Fibers for the Production of Food
Sordo, F., Janeček, E., Qu, Y., Michaud, V. J., Stellacci, F., Engmann, J., Wooster, T. J., & Sorin, F. (2019) · Advanced Materials · doi:10.1002/adma.201807282 · Cited by 59
Xia, Z., Han, Y., Du, H., McClements, D. J., Tang, Z., & Xiao, H. (2020) · LWT · doi:10.1016/j.lwt.2020.110224 · Cited by 59
Targeted Drug Delivery to Lymphocytes: A Route to Site-Specific Immunomodulation?
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100259a · Cited by 59
Self-citationMarkopoulos, C. J., Thoenen, F., Preisig, D., Symillides, M., Vertzoni, M., Parrott, N. J., Reppas, C. I., & Imanidis, G. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.10.017 · Cited by 58
Seljak, K. B., Berginc, K., Trontelj, J., Pobirk, A. Z., Kristl, A., & Gašperlin, M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24114 · Cited by 58
Tokle, T., Mao, Y., & McClements, D. J. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1003-x · Cited by 58
Impact of surfactants on the lipase digestibility of gum arabic-stabilized O/W emulsions
Yao, X., Wang, N., Fang, Y., Phillips, G. O., Jiang, F., Hu, J., Lu, J., Xu, Q., & Tian, D. (2013) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2013.04.013 · Cited by 58
Sassene, P. J., Fanø, M., Mu, H., Rades, T., Aquistapace, S., Schmitt, B., Cruz‐Hernandez, C., Wooster, T. J., & Müllertz, A. (2016) · Food & Function · doi:10.1039/c6fo00158k · Cited by 58
Khan, S., Yar, M. S., Fazil, M., Hassan, M. Q., Baboota, S., & Ali, J. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.011 · Cited by 58
Chitosan functionalized nanocochleates for enhanced oral absorption of cyclosporine A
Liu, M., Zhong, X., & Yang, Z. (2017) · Scientific Reports · doi:10.1038/srep41322 · Cited by 58
Pharmaceutical nanotechnology: Brief perspective on lipid drug delivery and its current scenario
Siram, K., Rahman, H., Balakumar, K., Duganath, N., Chandrasekar, R., & Hariprasad, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816506-5.00005-x · Cited by 58
Sharma, S., Singh, J., Afzal, M., Kaur, R., Imam, S. S., Alruwaili, N. K., Alharbi, K. S., Alotaibi, N. H., Alshammari, M. S., Kazmi, I. A., et al. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101674 · Cited by 58
Gu, L., Sun, R., Wang, W., & Xia, Q. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2021.105150 · Cited by 58
Parrott, N. J., Stillhart, C., Lindenberg, M., Wagner, B., Kowalski, K., Guerini, E., Djebli, N., & Meneses‐Lorente, G. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00463-y · Cited by 59
“concentrations of BS along the gastrointestinal tract to derive full biorelevant regional solubility profiles (17,18).”
BackgroundLiu, D., Pan, H., He, F., Wang, X., Li, J., Yang, X., & Pan, W. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87143 · Cited by 58
“It is well known that the diffusion across the unstirred water layer is a crucial barrier to the absorption of poorly water soluble drugs from the intestinal fluid.(30) The reduction of carvedilol particle size could promote its diffusion across the unstirred water layer and access the brush border membrane of enteroc…”
Ahmed, O. A. A., Badr-Eldin, S. M., Tawfik, M. K., Ahmed, T. A., El‐Say, K. M., & Badr, J. M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23834 · Cited by 58
Milinčić, D. D., Salević-Jelić, A. S., Kostić, A. Ž., Stanojević, S. P., Nedović, V., & Pešić, M. B. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2195519 · Cited by 57
“On the other hand, the same products formed by lipolysis of LCT easily accumulate on the oil-water interface and can potentially inhibit lipase activity (Ahmed et al. 2012; Gomes et al. 2021; McClements and Li 2010a, 2010b; Porter, Trevaskis, and Charman 2007).”
Xing, Q., Song, J. T., You, X., Xu, D., Wang, K., Song, J., Guo, Q., Li, P., Wu, C., & Hu, H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.07.061 · Cited by 57
McCartney, F., Rosa, M., & Brayden, D. J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110565 · Cited by 57
“The higher efficacy in the colon is likely due to the fact that the jejunum is routinely exposed to high concentrations of bile salt emulsifiers [65], and its plasma membranes are likely to better withstand surfactant-type PEs.”
BackgroundGu, C., Suleria, H. A. R., Dunshea, F. R., & Howell, K. S. (2020) · Antioxidants · doi:10.3390/antiox9080762 · Cited by 57
“The greater protective effects on polyphenols of medium-chain triglycerides could be possibly due to these triglycerides being digested to a greater degree than longer chain triglycerides, as MCFAs possess a higher dispersibility in the aqueous phase [37].”
BackgroundAmorphous Solid dispersions: a Robust Platform to Address Bioavailability Challenges
Newman, A. W., Nagapudi, K., & Wenslow, R. M. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.101 · Cited by 57
Immediate release pellets with lipid binders obtained by solvent-free cold extrusion
KRAUSE, J., Thommes, M., & Breitkreutz, J. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.020 · Cited by 57
“They are widely used with poorly water soluble drugs to enhance delivery and bioavailability [1] or as a taste masking agent for bitter tasting drugs [2].”
BackgroundNovel Lipid-Free Nanoformulation for Improving Oral Bioavailability of Coenzyme Q10
Zhou, H., Liu, G., Zhang, J., Sun, N., Duan, M., Yan, Z., & Xia, Q. (2014) · BioMed Research International · doi:10.1155/2014/793879 · Cited by 52
“benefits of lipids, such as their capacity to enhance waterinsoluble drug solubility in the intestinal milieu, recruit intestinal lymphatic drug transport, and alter enterocytebased drug transport and disposition, have made them very attractive candidates as carriers for oral formulations [17, 18].”
BackgroundSharma, A., Arora, K., Mohapatra, H., Sindhu, R. K., Bulzan, M., Cavalu, S. D., Paneshar, G., Elansary, H. O., El-Sabrout, A. M., Mahmoud, E. A., et al. (2022) · Molecules · doi:10.3390/molecules27092969 · Cited by 56
“Formulations that can enable the formation of a supersaturated state are usually classified into two groups: high-concentration drug solutions and high-energy or fast dissolving solid forms are achieved by modifications in wettability, morphology, or particle size [65] (Table 1).”
BackgroundSingh, S., Parikh, T., Sandhu, H. K., Shah, N. H., Malick, A. W., Singhal, D., & Serajuddin, A. T. M. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0994-7 · Cited by 56
“There has been a great interest in recent years in the development of lipid-based drug delivery systems; however the technology is still emerging and there is incomplete understanding how different components of lipid-based drug delivery systems interact and perform (5,16).”
BackgroundBandyopadhyay, S., Katare, O. P., & Singh, B. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.877885 · Cited by 57
“SNEDDS being primarily a carrier-based system is actively transported across the GI via carrier-mediated transport [21].”
BackgroundOral nanomedicine approaches for the treatment of psychiatric illnesses
Dening, T. J., Rao, S., Thomas, N., & Prestidge, C. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.047 · Cited by 56
Spray drying of fenofibrate loaded nanostructured lipid carriers
Xia, D., Shrestha, N., van de Streek, J., Mu, H., & Yang, M. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2016.01.001 · Cited by 56
“[1] Porter CJ, Trevaskis NL, Charman WN.”
BackgroundGomes, G. V. L., Sola, M. R., Marostegan, L. F. P., Jange, C. G., Cazado, C. P. S., Pinheiro, A. C., Vicente, A. A., & Pinho, S. C. (2016) · Journal of Food Engineering · doi:10.1016/j.jfoodeng.2016.08.001 · Cited by 56
“They are also lipophilic, which reduces their bioaccessibility (Porter et al., 2007) and restricts their incorporation into water-based matrices.”
BackgroundAli, M. A., Kataoka, N., Ranneh, A., Iwao, Y., Noguchi, S., Oka, T., & Itai, S. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00513 · Cited by 56
Boyd, B. J., Salim, M., Clulow, A. J., Ramirez, G., Pham, A. C., & Hawley, A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.027 · Cited by 56
Ghosh, S., Lalani, R., Patel, V., Bardoliwala, D., Maiti, K., Banerjee, S., Bhowmick, S., & Misra, A. R. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.011 · Cited by 56
Abuasal, B., Qosa, H., Sylvester, P. W., & Kaddoumi, A. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1790 · Cited by 55
“However, these models may not predict accurately the intestinal absorption because they lack the mucosal layer that separates the brush border membrane of the enterocytes from the bulk fluid phase of the small intestine lumen [16].”
BackgroundInfluentialNguyen, T., Tan, A., Santos, L. L., Ngo, D., Edwards, G. A., Porter, C. J. H., Prestidge, C. A., & Boyd, B. J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.012 · Cited by 55
Self-citationTan, A., Martin, A. L., Nguyen, T., Boyd, B. J., & Prestidge, C. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200409 · Cited by 55
Lang, B., McGinity, J. W., & Williams, R. O. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4003706 · Cited by 55
In vivo fate of lipid-silybin conjugate nanoparticles: Implications on enhanced oral bioavailability
Ma, Y., He, H., Xia, F., Li, Y., Lu, Y., Chen, D., Qi, J., Lü, Y., Zhang, W., & Wu, W. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.07.014 · Cited by 55
An update on polymer-lipid hybrid systems for improving oral drug delivery
Maghrebi, S., Prestidge, C. A., & Joyce, P. M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1605353 · Cited by 55
“Controlling lipase-provoked digestion is an important consideration for all lipid-based systems, specifically those delivering poorly water-soluble drugs, since the rate and extent of drug solubilization can be altered by modulating lipolysis kinetics [3].”
BackgroundKoehl, N. J., Holm, R., Kuentz, M., Jannin, V., & Griffin, B. T. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00305 · Cited by 55
Rahat, I., Rizwanullah, M., Gilani, S. J., Bin-Jumah, M. N., Imam, S. S., Kala, C., Asif, M., Alshehri, S., & Sharma, S. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102565 · Cited by 55
Nwabuife, J. C., Omolo, C. A., & Govender, T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.003 · Cited by 55
Trevaskis, N. L., Shackleford, D. M., Charman, W. N., Edwards, G. A., Gardin, A., Appel‐Dingemanse, S., Kretz, O., Galli, B., & Porter, C. J. H. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9860-z · Cited by 55
Self-citationPredictive models for oral drug absorption: from in silico methods to integrated dynamical models
Dokoumetzidis, A., Kalantzi, L., & Fotaki, N. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.4.491 · Cited by 55
“For example, it has been shown that for the in vitro dissolution of lipid-based formulations, the use of lipid digestion models are more appropriate when the fact that the in vivo performance of these formulations is affected by digestion and micellar solubilisation is taken into account [86-90] .”
BackgroundNingombam, L., Mana, T., Apum, G., Ningthoujam, R., & Singh, Y. D. (2024) · Environmental Nanotechnology Monitoring & Management · doi:10.1016/j.enmm.2024.100931 · Cited by 54
Zhang, X., Zhang, T., Zhou, X., Liu, H., Sun, H., Ma, Z., & Wu, B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23967 · Cited by 54
Khan, J., Hawley, A. M., Rades, T., & Boyd, B. J. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24634 · Cited by 54
Qureshi, A. A., Khan, D. A., Silswal, N., Saleem, S., & Qureshi, N. (2016) · doi:10.4172/2155-9880.1000434 · Cited by 54
Schultz, H. B., Thomas, N., Rao, S., & Prestidge, C. A. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.12.012 · Cited by 54
Self-microemulsifying tablets prepared by direct compression for improved resveratrol delivery
Seljak, K. B., Ilić, I. G., Gašperlin, M., & Pobirk, A. Z. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.06.065 · Cited by 54
Bannow, J., Yorulmaz, Y., Löbmann, K., Müllertz, A., & Rades, T. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118960 · Cited by 54
S‐layer Coated Emulsomes as Potential Nanocarriers
Üçışık, M. H., Küpcü, S., Debreczeny, M., Schuster, B., & Sleytr, U. B. (2013) · Small · doi:10.1002/smll.201203116 · Cited by 54
Lian, R., Lü, Y., Qi, J., Tan, Y., Niu, M., Guan, P., Hu, F., & Wu, W. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9666-2 · Cited by 54
In vitro methods to assess drug precipitation
Dai, W. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.040 · Cited by 54
Mechanisms and Extent of Enhanced Passive Permeation by Colloidal Drug Particles
Narula, A., Sabra, R., & Li, N. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00124 · Cited by 53
Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects
Rangaraj, N., Sampathi, S., Junnuthula, V., Kolimi, P., Mandati, P., Narala, S., Nyavanandi, D., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091807 · Cited by 53
“suggested three possible mechanisms for drug absorption: (1) alteration of the composition and character of the intestinal secretion, (2) intestinal lymphatic drug transport, and (3) enterocyte-based transport processes [143].”
BackgroundChopra, H., Mohanta, Y. K., Rauta, P. R., Ahmed, R., Mahanta, S., Mishra, P. K., Panda, P., Rabaan, A. A., Alshehri, A. A., Othman, B. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040581 · Cited by 54
“It has been observed that pharmaceuticals integrated into lipids and stabilized with different surfactants exhibit a high degree of permeability, as both the lipids and surfactants work as excellent permeation enhancers for medications in the gastrointestinal system [156].”
BackgroundFernandez, S., Jannin, V., Chevrier, S., Chavant, Y., Demarne, F., & Carrière, F. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1053-0 · Cited by 53
Mishra, A., Vuddanda, P. R., & Singh, S. (2014) · Journal of Nanotechnology · doi:10.1155/2014/351693 · Cited by 53
“The strategies such as prodrug synthesis, permeation enhancers, liposomes, microemulsions, polymeric nanoparticles, self-emulsifying drug delivery systems (SEDDS), and solid lipid nanoparticles (SLN) have been explored for the delivery of bioactives to intestinal lymphatics [19, 23, 24].”
BackgroundWooster, T. J., Moore, S. C., Chen, W., Andrews, H., Addepalli, R., Seymour, R. B., & Osborne, S. A. (2017) · RSC Advances · doi:10.1039/c7ra07804h · Cited by 53
Chaturvedi, S., Garg, A., & Verma, A. K. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101899 · Cited by 53
Prá, M. A. A. D., Vardanega, R., & Loss, C. G. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121159 · Cited by 53
Phan, S., Salentinig, S., Prestidge, C. A., & Boyd, B. J. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0168-5 · Cited by 52
Goyal, A., Sharma, V., Sihag, M. K., Arora, S., Singh, A. K., & Sabikhi, L. (2015) · Drying Technology · doi:10.1080/07373937.2015.1081929 · Cited by 52
“Evaluating the release behavior of functional ingredients from fortified foods under human gastrointestinal conditions is important to characterize the bioavailability of the functional component.([13])”
BackgroundTazi, A., Araújo, J. R., Mulet, C., Arena, E. T., Nigro, G., Pédron, T., & Sansonetti, P. J. (2018) · mBio · doi:10.1128/mbio.01493-18 · Cited by 52
“However, their regulation by environmental factors such as the microbiota remains only partially elucidated (9, 33, 37).”
BackgroundOjeda-Serna, I. E., Rocha‐Guzmán, N. E., Gallegos‐Infante, J. A., Cháirez‐Ramírez, M. H., Rosas‐Flores, W., Pérez‐Martínez, J. D., Moreno‐Jiménez, M. R., & González‐Laredo, R. F. (2019) · Food Research International · doi:10.1016/j.foodres.2019.03.011 · Cited by 52
Lu, X., & Huang, Q. (2019) · Food & Function · doi:10.1039/c9fo02029b · Cited by 52
Membrane interactions in drug delivery: Model cell membranes and orthogonal techniques
Bunea, A., Rønholt, S., Taboryski, R., & Nielsen, H. M. (2020) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102177 · Cited by 57
Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy
Manspeaker, M. P., & Thomas, S. N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.004 · Cited by 52
Polidoro, D. N., Temmerman, R., Devreese, M., Charalambous, M., Ham, L. V., Cornelis, I., Broeckx, B. J. G., Mandigers, P. J. J., Fischer, A., Storch, J., et al. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.899940 · Cited by 52
Alqahtani, S., Alayoubi, A. Y., Nazzal, S., Sylvester, P. W., & Kaddoumi, A. (2014) · Lipids · doi:10.1007/s11745-014-3923-6 · Cited by 51
Santos, J. C. C., Mansur, A. A. P., & Mansur, H. S. (2013) · Molecules · doi:10.3390/molecules18066550 · Cited by 51
“However, the exact roles of these glycoconjugates are not clearly understood due to the large number and complexity of the metabolic reactions involved, far beyond the simplified assumption that saccharides might play a role only in maintaining the structural properties of bioconjugates based on proteins and lipids [1…”
Background
Metadata
- Authors
- Porter, C. J. H., Trevaskis, N. L., & Charman, W. N.
- Affiliations
- Monash University (AU)
- Corresponding author
- Porter, Christopher J. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 231-248
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2069235788
- Cited by
- 1,824
- References
- 253
- Citations by year
- 2026: 88 · 2025: 87 · 2024: 67 · 2023: 89 · 2022: 119 · 2021: 108 · 2020: 140 · 2019: 101 · 2018: 117 · 2017: 121 · 2016: 125 · 2015: 119 · 2014: 120 · 2013: 128 · 2012: 94
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lipid-based drug delivery, oral bioavailability, lipophilic drugs, poorly water-soluble drugs, lipid excipients, first-pass metabolism, lipid-based formulations
- MeSH terms
- Administration, Oral, Animals, Pharmaceutical Preparations, Excipients, Humans, Intestinal Absorption, Lipids, Drug Design, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.